Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis
Open accessAbstract
Background and aims Large amounts of clot-bound lipoproteins were reported in proteomic analysis of plasma clot but their impact on fibrin clot properties is unknown. We investigated a contribution of lipid profile and apolipoproteins (apo) to the prothrombotic plasma fibrin clot phenotype in patients with aortic stenosis (AS).Methods In 138 patients with isolated severe AS, we determined serum apoA-I, A-II, B, C-II, C-III, E, oxidized low-density lipoprotein (OxLDL) and lipoprotein(a) concentrations. Plasma fibrin clot permeability (Ks), maximal absorbance (MaxAbs CLT2018 and MaxAbs Lys50), and fibrinolytic capacity were studied using 3 plasma-based lysis assays (CLT2018, CLT, and Lys50), and compared with well-matched patients without AS (control group).Results After adjustment for confounding factors, including statin use, only low-density lipoprotein cholesterol (LDL-C) and apoB levels were inversely associated with Ks. Triglycerides, apoC-II, and C-III were associated with MaxAbs CLT2018 and MaxAbs Lys50, explaining 56-64% of their variability. CLT2018 and CLT showed associations with total cholesterol, LDL-C, triglycerides, and OxLDL as well as with apoB, C-II, C-III, and E. ApoA-I, C-II, and C-III but not serum lipids were associated with Lys50. Only CLT2018 was associated with lipoprotein(a). ApoC-III, B, A-I, and E along with estimated glomerular filtration rate and OxLDL predicted hypofibrinolysis in multiple regression analysis. AS patients had higher lipoprotein(a) (+34.9%) and apoA-I (+25.9%) levels and less compact fibrin clots (-13.3% lower MaxAbs CLT2018, -53.2% lower MaxAbs Lys50, and +28.3% higher Ks) displaying higher susceptibility to lysis (-17.9% lower Lys50) in comparison with control group.Conclusions Apolipoproteins and OxLDL contribute to prothrombotic fibrin clot phenotype in severe AS. Moreover, apolipoproteins better than serum lipids predicted hypofibrinolysis, which provides additional argument for a role of elevated lipoproteins in the prothrombotic state.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAVS shares similar pathobiology with atherosclerotic vascular disease, involving intimal accumulation of apoB-containing particles, inflammation, and calcification.
“This is consistent with the notion that CAVS shares similar pathobiology with atherosclerotic vascular disease, involving intimal accumulation of apoB-containing particles, inflammation, and calcification17,44,45.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [45]
Cites
(2000) · PubMed · Cited by 13,173 · see citing works
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., Bonis, M. D., Hamm, C. W., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Muñoz, D. R., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,273 · see citing works
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982 · see citing works
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864 · see citing works
O’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560 · see citing works
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Boffa, M. B., & Koschinsky, M. L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r060582 · Cited by 309 · see citing works
Pathogenesis of Calcific Aortic Valve Disease
O’Brien, K. D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000227513.13697.ac · Cited by 294 · see citing works
Lisman, T., Leebeek, F. W. G., Mosnier, L. O., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.25481 · Cited by 280 · see citing works
Fibrin(ogen) and thrombotic disease
Ariëns, R. A. S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12229 · Cited by 191 · see citing works
Mills, J. D., Ariëns, R. A. S., Mansfield, M. W., et al. (2002) · Circulation · doi:10.1161/01.cir.0000033221.73082.06 · Cited by 186 · see citing works
Heritability of Clot Formation, Morphology, and Lysis
Carter, A. M., Cymbalista, C. M., Spector, T. D., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.153221 · Cited by 180 · see citing works
Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study
Nazarzadeh, M., Pinho-Gomes, A.-C., Bidel, Z., Dehghan, A., Canoy, D., Hassaine, A., Ayala Solares, J. R., Salimi-Khorshidi, G., Smith, G. D., Otto, C. M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa070 · Cited by 163 · see citing works
Sumaya, W., Wallentin, L. C., James, S. K., Siegbahn, A. G., Gabrysch, K., Bertilsson, M., Himmelmänn, A., Ajjan, R., & Storey, R. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy013 · Cited by 160 · see citing works
Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke
Undas, A., Podolec, P. S., Zawilska, K., Pieculewicz, M., Jedliński, I. M., Stępień, E. Ł., Konarska-Kuszewska, E., Węglarz, P., Duszyńska, M., Hanschke, E., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.532812 · Cited by 133 · see citing works
Self-citationPieters, M., Philippou, H., Undas, A., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14002 · Cited by 128 · see citing works
Self-citationInflammatory and metabolic mechanisms underlying the calcific aortic valve disease
Cho, K. I., Sakuma, I., Sohn, I. S., Jo, S., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.029 · Cited by 124 · see citing works
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa172 · Cited by 122 · see citing works
The dedicated “Lp(a) clinic”: A concept whose time has arrived?
Tsimikas, S., & Stroes, E. S. G. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.003 · Cited by 88 · see citing works
Undas, A., Plicner, D., Stępień, E. Ł., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02637.x · Cited by 83 · see citing works
Self-citationLipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis
Undas, A., Stępień, E. Ł., Tracz, W., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01903.x · Cited by 80 · see citing works
Self-citationMeltzer, M. E., Doggen, C. J. M., de Groot, P. G., Rosendaal, F. R., & Lisman, T. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07569.x · Cited by 71 · see citing works
Identification of Fibrin Clot-Bound Plasma Proteins
Talens, S., Leebeek, F. W. G., Demmers, J., & Rijken, D. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041966 · Cited by 64 · see citing works
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease
Neergaard‐Petersen, S., Hvas, A., Kristensen, S. D., Grove, E. L., Larsen, S., Phoenix, F. A., Kurdee, Z., Grant, P. J., & Ajjan, R. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0468 · Cited by 58 · see citing works
ApoC-III is a novel inducer of calcification in human aortic valves
Schlotter, F., de Freitas, R. C. C., Rogers, M. A., Blaser, M. C., Wu, P.-J., Higashi, H., Halu, A., Iqbal, F., Andraski, A. B., Rodia, C. N., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015700 · Cited by 49 · see citing works
Natorska, J., Marek, G., Hlawaty, M., Sadowski, J., Tracz, W., & Undas, A. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-09-0612 · Cited by 43 · see citing works
Self-citationMouriño-Álvarez, L., Martin, M. B., Gonzalez‐Calero, L., Martínez-Laborde, C., Sastre-Oliva, T., Moreno‐Luna, R., Lopez-Almodovar, L. F., Sanchez, P. L., Fernández‐Avilés, F., Vivanco, F., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.089 · Cited by 41 · see citing works
Dittrich, J., Beutner, F., Teren, A., Thiery, J., Burkhardt, R., Scholz, M. R., & Ceglarek, U. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.006 · Cited by 41 · see citing works
Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time
Ząbczyk, M., Stachowicz, A., Natorska, J., et al. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103487 · Cited by 41 · see citing works
Self-citationZąbczyk, M., Hońdo, Ł., Krzek, M., et al. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835a083c · Cited by 39 · see citing works
Fibrin clot properties in coronary artery disease: new determinants and prognostic markers
Larsen, J. B., & Hvas, A. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16113 · Cited by 39 · see citing works
Undas, A., Cieśla‐Dul, M., Drazkiewicz, T., & Sadowski, J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.06.005 · Cited by 38 · see citing works
Self-citationPieters, M., Guthold, M., Nunes, C. M. C., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1698460 · Cited by 37 · see citing works
Natorska, J., & Undas, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0861 · Cited by 34 · see citing works
Self-citationImpaired fibrinolysis is associated with the severity of aortic stenosis in humans
Natorska, J., Wypasek, E., Grudzień, G., Sadowski, J., & Undas, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12122 · Cited by 32 · see citing works
Self-citationBryk, A. H., Natorska, J., Ząbczyk, M., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103946 · Cited by 26 · see citing works
Self-citationDeterminants of plasma fibrin clot lysis measured using three different assays in healthy subjects
Siudut, J., Iwaniec, T., Plens, K., Pieters, M., & Undas, A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.10.014 · Cited by 26 · see citing works
Self-citationOrsi, F. A., Lijfering, W. M., van der Laarse, A., Ruhaak, L. R., Rosendaal, F. R., Cannegieter, S. C., & Cobbaert, C. M. (2019) · Clinical Epidemiology · doi:10.2147/clep.s196266 · Cited by 24 · see citing works
Siudut, J., Natorska, J., Wypasek, E., Wiewiórka, Ł., Ostrowska-Kaim, E., Wiśniowska‐Śmiałek, S., Plens, K., Legutko, J., & Undas, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062002 · Cited by 22 · see citing works
Self-citationIncreased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease
Mörtberg, J., Blombäck, M., Wallén, Å., et al. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000462 · Cited by 21 · see citing works
Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation
Matusik, P. T., Heleniak, Z., Papuga-Szela, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082476 · Cited by 20 · see citing works
Panes, O., Padilla, O., Matus, V., et al. (2011) · Platelets · doi:10.3109/09537104.2011.596957 · Cited by 16 · see citing works
Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction
Suski, M., Siudut, J., Ząbczyk, M., Korbut, R., Olszanecki, R., & Undas, A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.005 · Cited by 12 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-15525-4 · Cited by 3 · see citing works
“This is consistent with the notion that CAVS shares similar pathobiology with atherosclerotic vascular disease, involving intimal accumulation of apoB-containing particles, inflammation, and calcification 17,44,45 .”
- Authors
- Siudut, J., Natorska, J., Wypasek, E., Wiewiórka, Ł., Ostrowska-Kaim, E., Wiśniowska-Śmiałek, S., Plens, K., Musialek, P., Legutko, J., & Undas, A.
- Affiliations
- Jagiellonian University (PL)
- Andrzej Frycz Modrzewski Krakow University (PL)
- John Paul II Hospital (PL)
- Krakow Cardiovascular Research Institute (PL)
- Corresponding author
- Undas, Anetta
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 344
- Pages
- 49-56
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4207035431
- Cited by
- 16
- References
- 42
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 1
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
- ruj.uj.edu.pl
- Licence
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Blood properties and coagulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- aortic stenosis, apolipoproteins, lipoprotein(a), fibrin clot properties, fibrin clot permeability, fibrinolysis, hypofibrinolysis, oxidized LDL, prothrombotic phenotype, apolipoprotein C-III, apolipoprotein B, apolipoprotein A-I, apolipoprotein E
- MeSH terms
- Aortic Valve Stenosis, Apolipoproteins, Apolipoproteins B, Fibrin, Fibrinolysis, Humans, Lipoprotein(a), Proteomics, Fibrin Clot Lysis Time
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review